UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/15.01.25 Stock

Warrant

DE000HD3BKP6

Market Closed - BOERSE MUENCHEN 15:40:29 2024-05-24 EDT
1.67 EUR -3.47% Intraday chart for UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/15.01.25
Current month+15.17%
1 month+59.05%
Date Price Change
24-05-24 1.67 -3.47%
24-05-23 1.73 +9.49%
24-05-22 1.58 +3.27%
24-05-21 1.53 +21.43%
24-05-20 1.26 +9.57%

Real-time BOERSE MUENCHEN

Last update May 24, 2024 at 03:40 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HD3BKP
ISINDE000HD3BKP6
Date issued 2024-03-04
Strike 1,100 $
Maturity 2025-01-15 (235 Days)
Parity 10 : 1
Emission price 2.05
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.4
Lowest since issue 0.88
Delta0.18x
Omega 7.939
Premium38.46x
Gearing44.84x
Moneyness 0.7340
Difference Strike 292.6 $
Difference Strike %+26.60%
Spread 0.04
Spread %2.38%
Theoretical value 1.660
Implied Volatility 32.51 %
Total Loss Probability 88.21 %
Intrinsic value 0.000000
Present value 1.660
Break even 1,118.01 €
Theta-0.09x
Vega0.16x
Rho0.07x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4 USD
Average target price
850.8 USD
Spread / Average Target
+5.37%
Consensus